COLOGIC Colorectal Cancer Blood Test Launches in the Japanese Market

SASKATOON, Saskatchewan - Aug. 1, 2014 - PRLog -- SASKATOON, Saskatchewan, Canada – August 1, 2014 – Phenomenome Discoveries Inc. (“PDI”) congratulates its Japanese commercialization partner, BML Inc. (“BML”), on today’s market launch of the COLOGIC™ colorectal cancer test in Japan. First launched in Canada in 2012, COLOGIC is a simple blood test for colorectal cancer with no advance preparation or home stool sampling required. PDI developed the test in Saskatoon, SK, and after several successful clinical trials, including a 4923 patient Saskatchewan study, the COLOGIC test is being brought to Japanese residents today through partnership between Phenomenome Laboratory Services Inc. (PLSI), a wholly owned subsidiary of PDI, and BML. Additional studies performed by Osaka Medical University (“Osaka”) and Chiba University (“Chiba”) have further validated the test for Japan. As one of the leading diagnostic laboratories in Japan, BML delivers more than 2 million test results a day.  With 96 sales offices, 34 regional laboratories and over 3800 employees, BML is making every effort to ensure that COLOGIC is available to any Japanese resident who wishes to have the test.

Colorectal cancer is the leading cause of cancer deaths in Japanese females and the second leading cause of cancer deaths in Japanese males, resulting in over 45,000 combined deaths annually. The accurate identification of high risk persons can improve early detection that saves lives and reduce healthcare treatment dollars. COLOGIC requires only a small sample of blood to test for specific chemicals that are known to be at low levels in people with increased risk for colorectal cancer. As a simple blood test, it can be performed with ease and speed, often at the same time as other routine blood tests.

“Today we extend our congratulations to BML on the launch of COLOGIC in Japan,” says Dr. Dayan Goodenowe, CEO of Phenomenome Discoveries Inc. “I also want to recognize our Japanese medical research collaborators at Osaka and Chiba for critically evaluating and ultimately embracing PDI’s metabolomics technology, which can accurately identify disease risk before the disease happens, which is the critical first step towards early detection and prevention.  Improving health outcomes requires that innovative companies with delivery infrastructure, like BML, can rapidly translate validated clinical research findings from innovative medical researchers, like Osaka and Chiba into available products for Japanese doctors and patients.  This is what we are seeing here today.  We look forward to continuing to work with BML and our Japanese medical research collaborators on delivering innovative diagnostic products in Japan.”

“I am very pleased to offer COLOGIC to the Japanese market.  With the increasing prevalence and death rates of colorectal cancer in Japan, I believe this test will contribute to the awareness towards early detection of colon cancer,” comments Dr. Kensuke Kondo, President of BML. Inc.

About COLOGIC®

COLOGIC is a new simple way to test for increased colorectal cancer risk. It is a blood test that requires no advance preparation and no at home stool sampling. www.cologiclabtest.com

About Phenomenome Laboratory Services Inc.

Phenomenome Laboratory Services Inc. (PLSI) – Based in Saskatoon, Saskatchewan, Canada, PLSI is a CLIA certified medical laboratory, accredited by the College of Physicians and Surgeons of Saskatchewan (CPSS) and the College of American Pathologists (CAP).

About Phenomenome Discoveries Inc.

Phenomenome Discoveries Inc. (PDI) is a Saskatoon based human health research company, focusing on the discovery and development of novel disease screening, treatment and health monitoring products. Founded in 2000 and privately owned, PDI uses its patented biomarker discovery platform to discover and develop new biomarkers for cancer and neurodegenerative disorders and has launched therapeutics and diagnostics divisions based on the results of its research.  For more information please visit www.phenomenome.com

About BML Inc.

BML Inc., a Japanese corporation based in Tokyo Japan, provides a wide range of clinical laboratory tests ranging from general laboratory tests such as chemistry and hematologic tests to esoteric tests, including RIA, cellular, immunological, and DNA analysis, serving all clinical needs arising in medical institutions and hospitals.  BML serves more than two million test data a day for about 200,000 patients through laboratory tests sent from medical institutions and hospitals across the nation.  BML operates with corporate capital of 6,045,586,000 yen with over 3800 employees in the group company with 96 sales office and 34 regional laboratories and a main laboratory based in Kawagoe. For more information please visithttp://www.bml.co.jp/eng/index.html

Caution concerning forward-looking statements

Certain statements in this press release, including statements regarding availability of COLOGIC to Japanese patients and plans for a continuing relationship with BML and Japanese medical research collaborators are forward-looking statements within the meaning of Canadian securities legislation.     The words “may”, “will”, “could”, “should”, “would”, “suspect”, “outlook”, “believe”, “plan”, “anticipate”, “estimate”, “expect”, “intend”, “forecast”, “objective” and “continue” (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements.

Forward-looking statements contained in this press release are necessarily based on assumptions and information that, while considered reasonable to us, are inherently uncertain.  We caution that the foregoing list of important factors that may affect future results is not exhaustive.  Readers should not place undue reliance on any forward-looking statements. When reviewing our forward-looking statements, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.    Except as required by Canadian securities law, we do not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf; such statements speak only as of the date made.